COST-EFFECTIVENESS OF BREXUCABTAGENE AUTOLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN PATIENTS AGED 26 YEARS OR OLDER IN GREECE

被引：0
|
作者：
Vellopoulou, K. [1 ]
Tsirigotis, P. [2 ]
Chondropoulos, S. [2 ]
Konstantellos, I [2 ]
Qeodurasoy, N. [3 ]
Spousta, T. [4 ]
Van Hees, F. [4 ]
Smith, N. [4 ]
Doble, B. [5 ]
机构：
[1] Econcare LP, Athens, Greece
[2] Attikon Univ, Gen Hosp, Athens, Greece
[3] Gilead Sci Hellas, Palaio Faliro, Greece
[4] Maple Hlth Grp LLC, New York, NY USA
[5] Kite A Gilead Co, Santa Monica, CA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE265
引用
收藏
页码：S105 / S105
页数：1
相关论文
共 50 条
  • [41] FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
    O'Leary, Maura C.
    Lu, Xiaobin
    Huang, Ying
    Lin, Xue
    Mahmood, Iftekhar
    Przepiorka, Donna
    Gavin, Denise
    Lee, Shiowjen
    Liu, Ke
    George, Bindu
    Bryan, Wilson
    Theoret, Marc R.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2019, 25 (04) : 1142 - 1146
  • [42] Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
    Lia Gore
    Franco Locatelli
    Gerhard Zugmaier
    Rupert Handgretinger
    Maureen M. O’Brien
    Peter Bader
    Deepa Bhojwani
    Paul-Gerhardt Schlegel
    Catherine A. Tuglus
    Arend von Stackelberg
    Blood Cancer Journal, 8
  • [43] The Usefulness of Blinatumomab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Review
    Watakabe, Mai
    Arakawa, Yuki
    Irikura, Tomoya
    Honda, Mamoru
    Mitani, Yuichi
    Oshima, Koichi
    Watanabe, Atsuko
    Mori, Makiko
    Fukuoka, Kohei
    Koh, Katsuyoshi
    PEDIATRIC BLOOD & CANCER, 2021, 68
  • [44] Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective
    Wang, Xiao Jun
    Wang, Yi-Ho
    Ong, Matthew Jian Chun
    Gkitzia, Christina
    Soh, Shui Yen
    Hwang, William Ying Khee
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2022, 14 : 333 - 355
  • [45] BREXUCABTAGENE AUTOLEUCEL THERAPY FOR ADULT PATIENTS AFFECTED BY RELAPSED/ REFRACTORY B-ACUTE LYMPHOBLASTIC LEUKEMIA: THE ITALIAN REAL LIFE EXPERIENCE IN A CONTEXT OF THE NAMED PATIENT USE
    Sora, Federica
    Galli, Eugenio
    Xue, Elisabetta
    Restuccia, Francesco
    Pansini, Ilaria
    Giammarco, Sabrina
    Innocenti, Idanna
    Metafuni, Elisabetta
    Giglio, Fabio
    Autore, Francesco
    Fresa, Alberto
    Bacigalupo, Andrea
    Chiusolo, Patrizia
    Laurenti, Luca
    Salutari, Prassede
    Ciceri, Fabio
    Sica, Simona
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 219 - 219
  • [46] Efficacy and Tolerance of Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B- Cell Precursor Acute Lymphoblastic Leukemia : A Graall Study from the Descar-T Registry
    Rabian, Florence
    Beauvais, David
    Marchand, Tony
    Furst, Sabine
    Huynh, Anne
    Brissot, Eolia
    Maury, Sebastien
    Gabellier, Ludovic
    Chevallier, Patrice
    Loschi, Michael
    Quoc, Stephanie Nguyen
    Balsat, Marie
    Lafon, Ingrid
    Fayard, Amandine
    Camus, Vincent
    Simand, Celestine
    Moya, Niels
    Castilla-Llorente, Cristina
    Joris, Magalie
    Berceanu, Ana
    Thiebaut, Anne
    Lheritier, Veronique
    Gehlkopf, Eve
    Roth-Guepin, Gabrielle
    Leguay, Thibaut
    Boissel, Nicolas
    BLOOD, 2023, 142
  • [47] Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia
    Queudeville, Manon
    Stein, Anthony S.
    Locatelli, Franco
    Ebinger, Martin
    Handgretinger, Rupert
    Goekbuget, Nicola
    Gore, Lia
    Zeng, Yi
    Gokani, Priya
    Zugmaier, Gerhard
    Kantarjian, Hagop M.
    CANCER, 2023, 129 (09) : 1384 - 1393
  • [48] Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    Kantarjian, Hagop M.
    Zugmaier, Gerhard
    Brueggemann, Monika
    Wood, Brent L.
    Horst, Heinz A.
    Zeng, Yi
    Martinelli, Giovanni
    CANCERS, 2021, 13 (22)
  • [49] FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia
    Pulte, E. Dianne
    Vallejo, Jonathon
    Przepiorka, Donna
    Nie, Lei
    Farrell, Ann T.
    Goldberg, Kirsten B.
    McKee, Amy E.
    Pazdur, Richard
    ONCOLOGIST, 2018, 23 (11): : 1366 - 1371
  • [50] Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    Anthony Stein
    Janet L. Franklin
    Victoria M. Chia
    Deborah Arrindell
    William Kormany
    Jacqueline Wright
    Mandy Parson
    Hamid R. Amouzadeh
    Jessica Choudhry
    Guiandre Joseph
    Drug Safety, 2019, 42 : 587 - 601
12345